254 related articles for article (PubMed ID: 29111815)
21. The use of low-dose azathioprine in patients with Vogt-Koyanagi-Harada disease.
Kim SJ; Yu HG
Ocul Immunol Inflamm; 2007; 15(5):381-7. PubMed ID: 17972222
[TBL] [Abstract][Full Text] [Related]
22. A Novel Risk Stratification-Based Immunomodulatory Treatment Strategy for Vogt-Koyanagi-Harada Disease.
Jin K; Liang A; Song H; Xiao F; Gao F; Han X; Zhang M; Zhao C
Am J Ophthalmol; 2024 Jun; 262():25-33. PubMed ID: 38369223
[TBL] [Abstract][Full Text] [Related]
23. Band-shaped keratopathy in Chinese patients with Vogt-Koyanagi-Harada syndrome.
Yang P; Sun M
Cornea; 2011 Dec; 30(12):1336-40. PubMed ID: 21934492
[TBL] [Abstract][Full Text] [Related]
24. Management of pediatric Vogt-Koyanagi- Harada (VKH)-associated panuveitis.
Soheilian M; Aletaha M; Yazdani S; Dehghan MH; Peyman GA
Ocul Immunol Inflamm; 2006 Apr; 14(2):91-8. PubMed ID: 16597538
[TBL] [Abstract][Full Text] [Related]
25. Retinal vessel oxygen saturation is affected in uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; AlBloushi AF; Gikandi PW; Hardarson SH; Stefánsson E
Br J Ophthalmol; 2019 Dec; 103(12):1695-1699. PubMed ID: 30798260
[TBL] [Abstract][Full Text] [Related]
26. Vogt-Koyanagi-Harada disease in children.
Abu El-Asrar AM; Al-Kharashi AS; Aldibhi H; Al-Fraykh H; Kangave D
Eye (Lond); 2008 Sep; 22(9):1124-31. PubMed ID: 17479116
[TBL] [Abstract][Full Text] [Related]
27. The Relationship of Vogt-Koyanagi-Harada Syndrome to Ocular Hypertension and Glaucoma.
Veerappan M; Fleischman D; Ulrich JN; Stinnett SS; Jaffe GJ; Allingham RR
Ocul Immunol Inflamm; 2017 Dec; 25(6):748-752. PubMed ID: 27438521
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors in Vogt-Koyanagi-Harada disease.
Al-Kharashi AS; Aldibhi H; Al-Fraykh H; Kangave D; Abu El-Asrar AM
Int Ophthalmol; 2007; 27(2-3):201-10. PubMed ID: 17435968
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of Vogt-Koyanagi-Harada Disease: A Subanalysis From a Randomized Clinical Trial of Antimetabolite Therapies.
Shen E; Rathinam SR; Babu M; Kanakath A; Thundikandy R; Lee SM; Browne EN; Porco TC; Acharya NR
Am J Ophthalmol; 2016 Aug; 168():279-286. PubMed ID: 27296490
[TBL] [Abstract][Full Text] [Related]
30. Vogt-Koyanagi-Harada syndrome.
Moorthy RS; Inomata H; Rao NA
Surv Ophthalmol; 1995; 39(4):265-92. PubMed ID: 7725227
[TBL] [Abstract][Full Text] [Related]
31. Adalimumab Treatment in Patients with Vogt-Koyanagi-Harada Disease.
Couto C; Schlaen A; Frick M; Khoury M; Lopez M; Hurtado E; Goldstein D
Ocul Immunol Inflamm; 2018; 26(3):485-489. PubMed ID: 27775450
[TBL] [Abstract][Full Text] [Related]
32. Vogt-Koyanagi-Harada disease in Hispanic patients.
Sukavatcharin S; Tsai JH; Rao NA
Int Ophthalmol; 2007; 27(2-3):143-8. PubMed ID: 17380271
[TBL] [Abstract][Full Text] [Related]
33. [Vogt-Koyanagi-Harada syndrome: glucocorticoid therapy and visual prognosis].
Zhang M; Liu Q; Min H; Du H; Hu T
Zhonghua Yan Ke Za Zhi; 2002 Apr; 38(4):200-3. PubMed ID: 12133385
[TBL] [Abstract][Full Text] [Related]
34. Retinal functional changes measured by microperimetry after immunosuppressive therapy in patients with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; Al-Mezaine HS; Hemachandran S; Hariz R; Kangave D
Eur J Ophthalmol; 2012; 22(3):368-75. PubMed ID: 21928252
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease.
Read RW; Yu F; Accorinti M; Bodaghi B; Chee SP; Fardeau C; Goto H; Holland GN; Kawashima H; Kojima E; Lehoang P; Lemaitre C; Okada AA; Pivetti-Pezzi P; Secchi A; See RF; Tabbara KF; Usui M; Rao NA
Am J Ophthalmol; 2006 Jul; 142(1):119-24. PubMed ID: 16815259
[TBL] [Abstract][Full Text] [Related]
36. The effect on choroidal changes of the route of systemic corticosteroids in acute Vogt-Koyanagi-Harada disease.
Park UC; Cho IH; Lee EK; Yu HG
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1203-1211. PubMed ID: 28382438
[TBL] [Abstract][Full Text] [Related]
37. Effect of the duration of immunomodulatory therapy on the clinical features of recurrent episodes in Vogt--Koyanagi--Harada disease.
Errera MH; Fardeau C; Cohen D; Navarro A; Gaudric A; Bodaghi B; Westcott M; LeHoang P
Acta Ophthalmol; 2011 Jun; 89(4):e357-66. PubMed ID: 21251241
[TBL] [Abstract][Full Text] [Related]
38. The Choroidal Vascularity Index Decreases and Choroidal Thickness Increases in Vogt-Koyanagi-Harada Disease Patients During a Recurrent Anterior Uveitis Attack.
Liu S; Du L; Zhou Q; Zhang Q; Hu K; Qi J; Liang L; Zhou C; Kijlstra A; Yang P
Ocul Immunol Inflamm; 2018; 26(8):1237-1243. PubMed ID: 28914578
[TBL] [Abstract][Full Text] [Related]
39. Study of macular function by multifocal electroretinography in patients with Vogt-Koyanagi-Harada syndrome.
Yang P; Fang W; Wang L; Wen F; Wu W; Kijlstra A
Am J Ophthalmol; 2008 Nov; 146(5):767-71. PubMed ID: 18672226
[TBL] [Abstract][Full Text] [Related]
40. [Therapeutic regimen in Vogt-Koyanagi-Harada syndrome].
Yang P; Wang H; Zhou H; Zhong H; Li F; Huang X; Zhong H; Fu T
Zhonghua Yan Ke Za Zhi; 2002 Apr; 38(4):196-9. PubMed ID: 12133384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
